Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.47 |
| ▸ | ASPH | Q12797 | 1/20 | 0.47 |
| ▸ | KDM8 | Q8N371 | 1/20 | 0.47 |
| ▸ | KMO | O15229 | 2/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | PLAU | P00749 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | DHODH | Q02127 | 6/20 | 0.39 |
| ▸ | IGFBP3 | P17936 | 1/20 | 0.39 |
| ▸ | SLC22A12 | Q96S37 | 1/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | BLM | P54132 | 1/20 | 0.38 |
| ▸ | AGER | Q15109 | 1/20 | 0.38 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL755959 | 0.86 | KDM4E (0.47) | KDM4EASPHKDM8KMOALDH1A1 | |
| SCHEMBL28514184 | 0.81 | PLA2G2A (0.42) | KDM4EALDH1A1DHODHNPSR1L3MBTL1 | |
| SCHEMBL28608865 | 0.81 | PLAU (0.60) | KDM4EASPHKDM8ALDH1A1PLAU | |
| SCHEMBL9575355 | 0.81 | IGFBP3 (0.43) | KDM4EASPHKDM8ALDH1A1PLAU | |
| SCHEMBL4726584 | 0.80 | IGFBP3 (0.47) | KDM4EASPHKDM8ALDH1A1PLAU | |
| SCHEMBL755956 | 0.79 | KMO (0.42) | KDM4EASPHKDM8KMOALDH1A1 | |
| SCHEMBL13258529 | 0.79 | PLAU (0.41) | KDM4EASPHKDM8ALDH1A1PLAU | |
| SCHEMBL15844723 | 0.76 | PLAU (0.46) | KDM4EASPHKDM8GAAPLAU | |
| SCHEMBL755949 | 0.76 | PLAU (0.57) | KDM4EASPHKDM8ALDH1A1PLAU | |
| SCHEMBL13153181 | 0.76 | PLAU (0.38) | KDM4EASPHKDM8KMOALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 132 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-112358447-B | Synthesis method of 7-fluoroisoquinoline-1-carboxylic acid | 苏州康润医药有限公司 | 2022-04-12 | — | — | CN | claimed |
| CN-112358447-A | Synthesis method of 7-fluoroisoquinoline-1-carboxylic acid | 苏州康润医药有限公司 | 2021-02-12 | — | — | CN | claimed |
| CN-112358447-B | Synthesis method of 7-fluoroisoquinoline-1-carboxylic acid | 苏州康润医药有限公司 | 2022-04-12 | — | — | CN | disclosed |
| CN-112358447-B | Synthesis method of 7-fluoroisoquinoline-1-carboxylic acid | 苏州康润医药有限公司 | 2022-04-12 | — | — | CN | disclosed |
| CN-112358447-B | Synthesis method of 7-fluoroisoquinoline-1-carboxylic acid | 苏州康润医药有限公司 | 2022-04-12 | — | — | CN | disclosed |
| CN-112358447-A | Synthesis method of 7-fluoroisoquinoline-1-carboxylic acid | 苏州康润医药有限公司 | 2021-02-12 | — | — | CN | disclosed |
| CN-112358447-A | Synthesis method of 7-fluoroisoquinoline-1-carboxylic acid | 苏州康润医药有限公司 | 2021-02-12 | — | — | CN | disclosed |
| CN-112358447-A | Synthesis method of 7-fluoroisoquinoline-1-carboxylic acid | 苏州康润医药有限公司 | 2021-02-12 | — | — | CN | disclosed |
| US-20170355689-A1 | HEPATITIS C VIRUS INHIBITOR | BRISTOL MYERS SQUIBB CO (US) | 2017-12-14 | — | — | US | disclosed |
| US-20170355689-A1 | HEPATITIS C VIRUS INHIBITOR | BRISTOL MYERS SQUIBB CO (US) | 2017-12-14 | — | — | US | disclosed |
| EP-2601188-B1 | HEPATITIS C VIRUS INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2017-10-18 | — | — | EP | disclosed |
| US-20090202483-A1 | Hepatitis C Virus Inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2009-08-13 | — | — | US | disclosed |
| US-20090202483-A1 | Hepatitis C Virus Inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2009-08-13 | — | — | US | disclosed |
| CN-100471838-C | VLA-4 inhibitors | DAIICHI SEIYAKU CO (JP) | 2009-03-25 | — | — | CN | disclosed |
| CN-100396680-C | Vla-4 inhibitors | DAICHI PHARMACEUTICAL CO LTD (JP) | 2008-06-25 | — | — | CN | disclosed |
| US-7157487-B2 | Vla-4 inhibitors | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2007-01-02 | — | — | US | disclosed |
| CN-1699363-A | Vla-4 inhibitors | DAICHI PHARMACEUTICAL CO LTD (JP) | 2005-11-23 | — | — | CN | disclosed |
| US-20040110945-A1 | Vla-4 inhibitors | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2004-06-10 | — | — | US | disclosed |
| CN-1483024-A | Vla-4 inhibitors | ��һ��������ҩ��ʽ���� | 2004-03-17 | — | — | CN | disclosed |
| EP-1346982-A1 | VLA-4 INHIBITORS | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2003-09-24 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170355689-A1 | HEPATITIS C VIRUS INHIBITOR | HAVCR2, LIPC, PYGL | KDM4E 3740/4885ASPH 2415/4885KDM8 3263/4885 |
| US-20040110945-A1 | Vla-4 inhibitors | VCAM1, ITGA1, ITGB4 | KDM4E 1271/4885ASPH 820/4885KDM8 1396/4885 |
| US-20090202483-A1 | Hepatitis C Virus Inhibitors | HAVCR2, PYGL, HCCS | KDM4E 3857/4885ASPH 2504/4885KDM8 3184/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.